Repligen Co. (NASDAQ:RGEN) Shares Bought by abrdn plc

abrdn plc grew its stake in Repligen Co. (NASDAQ:RGEN) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,192 shares of the biotechnology company’s stock after purchasing an additional 71 shares during the quarter. abrdn plc’s holdings in Repligen were worth $934,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Handelsbanken Fonder AB boosted its stake in Repligen by 20.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 10,733 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 1,810 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of Repligen by 130.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 11,500 shares of the biotechnology company’s stock valued at $1,829,000 after purchasing an additional 6,500 shares during the last quarter. Raymond James & Associates grew its holdings in Repligen by 3.5% in the 3rd quarter. Raymond James & Associates now owns 67,219 shares of the biotechnology company’s stock valued at $10,688,000 after buying an additional 2,283 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Repligen by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after acquiring an additional 137,220 shares during the last quarter. Finally, Forsta AP Fonden acquired a new position in shares of Repligen during the 3rd quarter valued at about $1,908,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $166.14 on Tuesday. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.28 billion, a P/E ratio of 230.75, a PEG ratio of 5.46 and a beta of 1.02. The firm has a fifty day moving average price of $183.37 and a 200 day moving average price of $173.88.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. During the same quarter in the previous year, the business earned $0.68 earnings per share. The firm’s revenue was down 16.6% compared to the same quarter last year. Sell-side analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 in the last ninety days. 1.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

RGEN has been the topic of a number of analyst reports. Stifel Nicolaus lifted their target price on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $196.70.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.